Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib + Pembrolizumab in Acral/Mucosal Melanoma
NCT05436990Phase 2Terminated
- Sponsor
- Yonsei University
- Start
- Feb 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vactosertib in acral lentiginous melanoma (ALM), mucosal melanoma (MM), sponsored by Yonsei University. Started Feb 2023; status: terminated.
02
Drugs
vactosertib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT05436990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436990.